Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.69 |
| ▸ | CDK8 | P49336 | 6/20 | 0.69 |
| ▸ | CDK19 | Q9BWU1 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429106 | 0.83 | CCNC (0.79) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL18429103 | 0.82 | CCNC (1.00) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL18429388 | 0.79 | CCNC (0.71) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL6987272 | 0.76 | MEN1 (0.57) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL6994907 | 0.75 | MEN1 (0.58) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL6985502 | 0.74 | KDM4E (0.59) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL1857463 | 0.73 | NPSR1 (1.00) | MEN1KMT2ANPSR1KDM4EADORA3 | |
| SCHEMBL7244568 | 0.73 | NPSR1 (0.95) | MEN1KMT2ANPSR1KDM4EADORA3 | |
| SCHEMBL6991615 | 0.72 | MEN1 (0.51) | CCNCCDK8CDK19MEN1KMT2A | |
| SCHEMBL2561361 | 0.71 | MEN1 (0.59) | MEN1KMT2ANPSR1KDM4EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133075-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-9745325-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-3133075-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | CDK8, CDK9, CDK19 | CCNC 29/4885CDK8 1/4885CDK19 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.